Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OAK
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2023 Results assessing the transcriptomic analysis with multiplex immunohistofluorescence (mIHF) on tumor tissue and with proteomic profiling of plasma from patients included in the open-label, randomized phase 2 POPLAR (NCT01903993) and phase 3 OAK trials (NCT02008227), which evaluated atezolizumab versus docetaxel in patients with NSCLC who progressed following platinum-based chemotherapy, published in the Clinical Cancer Research.
    • 24 Oct 2023 Results (n=412) assessing the modified Glasgow prognostic score (mGPS) at the time of first staging (6 weeks after the start of therapy) in patients with non-small cell lung cancer treated with atezolizumab, presented at the 48th European Society for Medical Oncology Congress.
    • 06 Jun 2023 Results demonstrating the atezolizumab response score (ARS), uses digital pathology features of the shape and size of nuclei in the tumor epithelium to predict response to atezolizumab in patients from POPLAR and OAK trials with non-small cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top